I-Corps: Barcode Blotting Diagnostic Technology for Point-of-Care Testing

慢性传染病在发达国家和发展中国家的扩散表明，迫切需要使目前缓慢和劳动密集型的实验室诊断更便宜和更便携，具有必要的灵敏度和特异性，以作为现场诊断测定。加州大学伯克利分校开发的集成条形码诊断工具显着降低了检测成本和时间，同时为医疗从业者提供了关于疾病状态的关键新信息，以准确地现场筛查和治疗包括HIV/HCV（丙型肝炎）合并感染在内的传染病。 拟议的工作将使原型设计，需求评估和收集客户和行业反馈，以开发第一个用于全血生物标志物免疫测定的多路电泳平台。 该团队的核心技术是一种三维水凝胶基质，可以捕获和检测特异性抗体（IgG）。存在引入集成诊断平台技术的机会，该集成诊断平台技术保留了当前筛查诊断的低成本、小占地面积、易用性和便携性，同时增加了目前在大型集中实验室中运行的缓慢的、人工劳动密集型的确认诊断所提供的高特异性（准确性）。 生物功能化聚丙烯酰胺光图案化技术的关键进展提供了具有简单和快速操作的多重条形码印迹免疫测定。 将复杂和高性能的检测转化为单一的低成本便携式工具可以显着推进艾滋病毒和丙型肝炎（HCV）的诊断。将条形码印迹技术用于快速（30分钟）和多重HIV/HCV筛查诊断的商业化将为改善世界医疗保健做出重大贡献，同时也为进入未来几年显着增长的商业市场提供了机会。

The proliferation of chronic infectious diseases in the developed and developing world demonstrates the vital need to make presently slow and labor intensive laboratory diagnostics cheaper and more portable with the requisite sensitivity and specificity to be deployed as field diagnostic assays. The integrated barcode diagnostic tool developed at UC Berkeley significantly reduces assay cost and time while providing health practitioners with critical new information on disease state for accurate on-the spot screening and treatment of infectious diseases including HIV/HCV (hepatitis C) co-infection. The proposed work will enable prototyping, needs assessment and collection of customer and industry feedback towards development of the first multiplexed electrophoretic platform for immunoassay of biomarkers from whole blood. The team's core technology is a three-dimensional hydrogel matrix which enables specific antibody (IgG) capture and detection. There exists an opportunity to introduce an integrated diagnostic platform technology preserving the low cost, small footprint, ease-of-use and portability of current screening diagnostics while adding the high-specificity (accuracy) provided by slow, manual-labor intensive confirmatory diagnostics that are presently run in large centralized laboratories. The key advances in biologically-functionalized polyacrylamide photo-patterning technology provide a multiplexed barcode blotting immunoassay with simple and fast operation. Transforming sophisticated and high performance assays into a single low-cost portable tool can significantly advance diagnosis of HIV and hepatitis C (HCV). Commercializing the barcode blotting technology for rapid (30 min) and multiplexed HIV/HCV screening diagnostics would make a major contribution to improving world healthcare while also providing entry into a commercial market primed for significant growth over the next several years.